Literature DB >> 29536305

Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model.

S N Shchelkunov1,2,3, I A Razumov4, I V Kolosova5, A V Romashchenko4, E L Zavjalov4.   

Abstract

The possibility of glioblastoma virotherapy at intravenous injection of the LIVP-GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP-GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP-GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.

Entities:  

Mesh：

Year:  2018        PMID： 29536305     DOI： 10.1134/S1607672918010088

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.834


  13 in total

1.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

2.  First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Authors:  Herbert J Zeh; Stephanie Downs-Canner; J Andrea McCart; Zong Sheng Guo; Uma N M Rao; Lekshmi Ramalingam; Stephen H Thorne; Heather L Jones; Pawel Kalinski; Eva Wieckowski; Mark E O'Malley; Manijeh Daneshmand; Kang Hu; John C Bell; Tae-Ho Hwang; Anne Moon; Caroline J Breitbach; David H Kirn; David L Bartlett
Journal:  Mol Ther       Date:  2014-10-08       Impact factor: 11.454

3.  Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Authors:  Xueqing Lun; Wenqing Yang; Tommy Alain; Zhong-Qiao Shi; Huong Muzik; John W Barrett; Grant McFadden; John Bell; Mark G Hamilton; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  The role of thymidine kinase in cancer diseases.

Authors:  Ondrej Topolcan; Lubos Holubec
Journal:  Expert Opin Med Diagn       Date:  2008-02

5.  [Oncolytic viruses in the therapy of gliomas].

Authors:  N V Gubanova; A S Gaĭtan; I A Razumov; V A Mordvinov; A L Krivoshapkin; S V Netesov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2012 Nov-Dec

6.  Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

Authors:  Qian Zhang; Yong A Yu; Ena Wang; Nanhai Chen; Robert L Danner; Peter J Munson; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

7.  Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Authors:  XueQing Lun; Jennifer Chan; Hongyuan Zhou; Beichen Sun; John J P Kelly; Owen Owen Stechishin; John C Bell; Kelley Parato; Kang Hu; Dominique Vaillant; Jiahu Wang; Ta-Chiang Liu; Caroline Breitbach; David Kirn; Donna L Senger; Peter A Forsyth
Journal:  Mol Ther       Date:  2010-08-31       Impact factor: 11.454

8.  The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Authors:  Kelley A Parato; Caroline J Breitbach; Fabrice Le Boeuf; Jiahu Wang; Chris Storbeck; Carolina Ilkow; Jean-Simon Diallo; Theresa Falls; Joseph Burns; Vanessa Garcia; Femina Kanji; Laura Evgin; Kang Hu; Francois Paradis; Shane Knowles; Tae-Ho Hwang; Barbara C Vanderhyden; Rebecca Auer; David H Kirn; John C Bell
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

9.  Genome stability of the vaccine strain VACΔ6.

Authors:  R A Maksyutov; S N Yakubitskiy; I V Kolosova; T V Tregubchak; A N Shvalov; E V Gavrilova; S N Shchelkunov
Journal:  Vavilovskii Zhurnal Genet Selektsii       Date:  2022-07

10.  Erratum to: Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Authors:  Elena P Goncharova; Julia S Ruzhenkova; Ivan S Petrov; Sergey N Shchelkunov; Marina A Zenkova
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531
View more
  3 in total

1.  Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme.

Authors:  Chase Burton; Arabinda Das; Daniel McDonald; William A Vandergrift; Sunil J Patel; David Cachia; Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-11-19

2.  Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Alexei S Kabanov; Tatiana V Bauer; Leonid E Bulychev; Stepan A Pyankov
Journal:  Viruses       Date:  2020-07-24       Impact factor: 5.048

3.  Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Kseniya A Titova; Stepan A Pyankov; Alexander A Sergeev
Journal:  Pathogens       Date:  2021-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.